In their randomised single centre clinical trial, Grunebaum and colleagues have assessed whether there is any benefit to the use of adjunctive ketamine on suicidal ideation in individuals with major depressive disorder. Researchers randomly allocated 82 voluntarily hospitalised eligible patients to intravenous infusion of ketamine (0·5 mg/kg) or midazolam (0·02 mg/kg). The researchers noted that although the Scale for Suicidal Ideation (SSI) score 24 hours after infusion reduced from baseline in both groups, the ketamine group experienced a 4·96 points greater reduction in SSI score than the midazolam group (95% CI 2·33–7·59; Cohen's d=0·75; p<0·001).

中文翻译：

---

研究综述

在他们的随机单中心临床试验中，Grunebaum及其同事评估了在患有重度抑郁症的人中使用氯胺酮辅助自杀意念是否有任何益处。研究人员随机分配了82名自愿入院的合格患者，以氯胺酮（0·5 mg / kg）或咪达唑仑（0·02 mg / kg）进行静脉输注。研究人员指出，尽管两组输液后24小时的自杀意念量表（SSI）得分均较基线水平有所降低，但氯胺酮组的SSI得分却比咪达唑仑组降低了4·96点（95％CI 2·33）。 –7·59；科恩（Cohen）d = 0·75； p <0·001）。